Neural transplantation in Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 24, Issue 4, 1997, Pages 292-301

  Mehta, V ^a   Spears, J ^a   Mendez, I ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL MEDULLA; BASAL GANGLION; DOPAMINE BRAIN LEVEL; FETAL TISSUE TRANSPLANTATION; HUMAN; NERVE TRANSPLANTATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031430908     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100032959     Document Type: Review

References (125)

1. Barbeau A, Mars H, Gillo-Joffroy L, et al. A proposed classification of dopa-induced dyskinesia. In: Barbeau A, Macdowell FH, eds. L-Dopa and Parkinsonism. Philadelphia: Davis, 1970: 118-123.
2. Rajput AH, Stern W, Laverly WH. Chronic low dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991-997.
3. Freed WJ, Hoffer BJ, Olson, et al. Transplantation of catecholamine-containing tissues to restore the functional capacity of the damaged nigrostriatal system. In: Sladek JR Jr, Gash DM, eds. Neural Transplants. Development and Function. New York: Plenum Press, 1984: 737-402.
4. Sladek JR Jr, Gash DM. Review article. Nerve-cell grafting in Parkinson's disease. J Neurosurg 1988; 68: 337-351.
5. Fisher LJ, Gage FH. Intracerebral transplantation: basic and clinical applications to the neostriatum. FASEB 1994; 8: 489-496.
6. Hitchcock ER. Current trends in neural transplantation. Neurol Res 1995; 17: 33-37.
7. Lindvall O. Neural Transplantation. Cell Transplantation 1995; 4: 391-400.
8. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19: 102-109.
9. Freed WJ. Intracerebral adrenal medulla grafts: a review. Exp Neurol 1990; 110: 139-166.
10. Thompson WG. Successful brain grafting. NY Med J 1890; 51: 701.
11. Saltykow S. Versuche uber Gehirn replantation, Zugleich ein Beitrag zur Kenntniss reactiver Vorgange an den zelligen Gehirneelementen. Arch Psychiatr Nervenkr 1905; 40: 329-388.
12. Dunn E. Primary and secondary findings in a series of attempts to transplant cerebral cortex in albino rats. J Comp Neurol 1917; 22: 565-582.
13. Legros Clark WE. Neuronal differentiation in implanted foetal cortical tissue. J Neurol Psychiatry 1940; 3: 263-284.
14. May RM. Connexions entre des cellules cerebrales et des muscles de la cause dans leur greffe blephoplastique intraoculaire simultanee chez la souris. Anat Microsc Morphol Exp 1949; 38: 145.
15. Flenko B, Szentagothai J. Oestrogen sensitive nervous structures in the hypothalamus. Acta Endocrinol 1957; 26: 121-127.
16. Halasz B, Pupp L, Uhlarik S, et al. Growth of hypophysectomized rats bearing pituitary transplant in the hypothalamus. Acta Physiol Hung 1963; 23: 287-292.
17. Halasz B, Pupp L, Uhlarik S, et al. Further studies on the hormone secretion of the anterior pituitary transplanted into the hypophysiotrophic areas of the rat hypothalamus. Endocrinology 1965; 77: 343-355.
18. Das GD. Transplantation of embryonic neural tissue in the mammalian brain. Growth and differentiation of neuroblasts from various regions of the embryonic brain in the cerebellum of neonate rats. J Life Sci 1974; 4: 93-124.
19. Lund R, Hauscha S. Transplanted neural tissue develops connections with host rat brain. Science 1976; 193: 582-584.
20. Bjorklund A, Kramer LF, Stenevi U. Cholinergic reinervation of rat hippocampus by septal implants is stimulated by perforant path lesion. Brain Res 1979; 173: 57-64.
21. Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177:555-560.
22. Bjorklund A, Stenevi U. Reformation of the severed septohippocampal cholinergic pathway in the adult rat by transplanted septal neurons. Cell Tissue Res 1977; 185: 289-302.
23. Bjorklund A, Stenevi U, Svendgaard NA. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature 1976; 262: 787-790.
24. Bjorklund A, Dunnett SB, Stenevi U, et al. Reinnervation of the denervated striatum by substantia nigra transplants. Functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 1980; 199: 307-333.
25. Perlow MJ, Freed WJ, Hoffer BJ, et al. Brain grafts reduce motor abnormalities produced by destruction of nigro-striatal dopamine system. Science 1979; 204: 643-647.
26. Freed WJ, Perlow MJ, Karoum F, et al. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioural, biochemical, and histochemical studies. Ann Neurol 1980; 8: 510-519.
27. Freed WJ, Morihisa JM, Spoor E, et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion induced rotational behaviour. Nature 1981; 292: 351-352.
28. Redmond DE Jr, Sladek JR Jr, Roth RH, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1986; 1: 1125-1127.
29. Sladek JR Jr, Redmond DE Jr, Collier TJ, et al. Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. Prog Brain Res 1988; 78: 497-506.
30. Sladek JR Jr, Collier TJ, Haber SN, et al. Survival and growth of fetal catecholamine neurons transplanted into primate brain. Brain Res Bull 1986; 17: 809-818.
31. Stevens JR, Phillips I, Freed WJ, Poltorak M. Cerebral transplants for seizures: preliminary results. Epilepsia 1988; 29: 731-737.
32. Holmes GL, Thompson JL, Huh K, Stuart JD, Carl GF. Effects of neural transplantation on seizures in the immature genetically epilepsy prone rat. Exp Neurol 1992; 116: 52-63.
33. Deckel AW, Robinson RG, Coyle JT, Sanberg PR. Reversal of longterm locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. Eur J Pharmacol 1983; 93: 287-288.
34. Fine A, Dunnett SB, Bjorklund A, Iversen SD. Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer's disease. Proc Natl Acad Sci USA 1985; 82: 5227-5230.
35. Bregman BS. Spinal cord transplants permit the growth of serotonergic axons across the site of neonatal spinal cord transection. Dev Brain Res 1987; 34: 265-279.
36. Das GD. Neural transplantation in the spinal cord of adult rats. J Neurol Sci 1983; 62: 191-210.
37. Wurtman RJ, Pohorecky LA, Baliga BS. Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. Pharmacol Rev 1972; 24: 411-426.
38. Unsicker K, Rieffert B, Ziegler W. Effects of cell culture conditions, nerve growth factor, dexamethasone and cyclic AMP on adrenal chromaffin cells in vitro. Adv Biochem Pharmacol 1980; 25: 51-59.
39. Winn SR, Wahlberg L, Tresro PA, et al. An encapsulated dopamine-releasing polymer alleviates experimental Parkinsonian in rats. Exp Neurol 1989; 105: 244-250.
40. Stromberg I, Herrera-Marschitz M, Hultgren L, et al. Adrenal medullary implants in the dopamine denervated rat striatum. 1. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res 1984; 297: 41-51.
41. Stromberg I, Herrera-Marschitz M, Ungerstedt U, et al. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fibre growth and rotational behaviour. Exp Brain Res 1985; 60: 335-349.
42. Brown VJ, Dunnett SB. Comparison of adrenal and foetal nigral grafts on drug-induced rotation in rats with 6-OHDA lesions. Exp Brain Res 1989; 78: 214-218.
43. Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985; 62: 169-173.
44. Lindvall O, Backlund EO, Farde L, et al. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to putamen. Ann Neurol 1987; 22: 457-468.
45. Madrazo I, Drucker-Colin R, Diaz V, et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in Parkinson's disease: a report of two cases. N Engl J Med 1987; 316: 831-834.
46. Allen GS, Burns RS, Tulipan NB, et al. Adrenal medullary transplantation to the caudate nucleus in Parkinsons disease. Initial results in 18 patients. Arch Neurol 1989; 46: 487-491.
47. Bakay RAE. Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons GRAFT project. Restorative Neurol Neurosci 1989; 1: 158.
48. Flores EG. Is autologous transplant of adrenal medulla into the striatum an effective therapy for Parkinson's disease? Restorative Neurol Neurosci 1990; 1: 182.
49. Kelly PJ, Ahlskog JE, Van Heerden JA, et al. Adrenal medullary autograft transplantation into the striatum of Parkinson's disease. Mayo Clin Proc 1989; 64: 282-290.
50. Goetz CG, Stebbins GT, Klawans, et al. United Parkinson Foundation Neural Transplantation Registry (1991) United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1 and 2 year follow-up. Neurology 1991; 41: 1719-1722.
51. Apuzzo MLJ, Neal JH, Waters CH, et al. Utilization of unilateral and bilateral sterotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations 1990; 26: 746-757.
52. Jiang N, Jiang C, Tang Z, et al. Human foetal brain transplant trials in the treatment of Parkinsonism. Acta Acad Medicin Shangai 1987; 14(1): 77.
53. Lindvall O, Rehncrona S, Gustavii B, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 1988; 2: 1483-1484.
54. Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-631.
55. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 547.
56. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-165.
57. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-180.
58. Madrazo I, Leon V, Torres C, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 1988; 318: 51.
59. Madrazo I, Franco-Bourland R, Ostrosky-Solis F, et al. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of parkinsonian patients. Arch Neurol 1990; 47: 1281-1285.
60. Madrazo I, Franco-Bourland R, Aguilera M, et al. Fetal ventral mesencephalon brain homotransplantation in Parkinson's disease: the Mexican experience. In: Lindvall O, Bjorklund A, Widner H, eds. Intracerebral Transplantation in Movement Disorders. Restorative Neurology, Vol 4, Amsterdam: Elsevier, 1991: 123-129.
61. Madrazo I, Franco-Bourland R, Ostrosky-Solis F, et al. Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinsons disease. The Mexican experience. Prog Brain Res 1990b; 82: 593-602.
62. Molina H, Quinones R, Alvarez L, et al. Transplantation of human fetal mesencephalic tissue in caudate nucleus as treatment for Parkinson's disease: the Cuban experience. In: Lindvall O, Bjorklund A, Widner H. eds. Intracerebral Transplantation in Movement Disorders. Restorative Neurology, Vol. 4, Amsterdam: Elsevier, 1991: 99-110.
63. Hitchcock ER, Clough C, Hughes R, Kenny B. Embryos and Parkinson's disease. Lancet 1988; 1: 1274.
64. Hitchcock ER, Kenny BG, Clough CG, et al. Stereotactic implantation of foetal mesencephalon (STIM): the UK experience. In: Dunnett SB, Richards S-J, eds. Neural Transplantation: From Molecular Basis to Clinical Applications. Progress in Brain Research. Amsterdam: Elsevier, 1990: 723-728.
65. Henderson BTH, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 1991; 48: 822-827.
66. Freed CR, Breeze RE, Rosenberg NL, et al. Transplantation of human fetal dopamine cells for Parkinson's disease: results at 1 year. Arch Neurol 1990; 47: 505-512.
67. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549-1555.
68. Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the clinica Puerta de Hierro experience. Transplant Pro 1995; 27; 1: 1395-1400.
69. Freeman TB, Olanow CW, Hauser, RA et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38(3): 379-388.
70. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327: 1556-1563.
71. Peschanski M, Defer G, Guyen JP, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-499.
72. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327: 1541-1548.
73. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-1124.
74. Freed CR, Breeze RE, Leehey MA, et al. Eight years experience with fetal neurotransplantation in patients with advanced Parkinson's disease. Soc Neurosci Abst 1996; 22(2): 481 .3.
75. Wu CY, De Zhou M, Bao X-F, et al. The combined method of transplantation of foetal substantia nigra and Stereotactic thalamotomy for Parkinson's disease. Br J Neurosurg 1994; 8: 709-716.
76. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantation (CAPIT). Mov Disord 1992; 7: 2-13.
77. Freeman TB, Spence MS, Boss BD, et al. Development of dopaminergic neurons in the human substantia nigra. Exp Neurol 1991:113:344-353.
78. Verney C, Zecevic N, Nikolic B, et al. Early evidence of catecholaminergic cell groups in 5 and 6 week old human embryos using tyrosine hydroxylase and dopamine-B-hydroxylase immunocytochemistry. Neurosci Lett 1991; 131: 121-124.
79. Freeman TB, Sanberg PR, Navelt GM, et al. Influence of donor age on the survival of solid and suspension intraparenchymal human embryonic micrografts. Cell Transplant 1995; 4: 141-145.
80. German DC, Schlosselberg DS, Woodward DJ. Three dimensional computer reconstruction of midbrain dopaminergic neuronal population from mouse to man. J Neural Transm 1983; 57: 243-254.
81. Brundin P, Strecker RE, Widner H, et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug induced behaviour, and dopamine release. Exp Brain Res 1988; 70: 192-208.
82. Gash DM, Bresjanac M, Junn F, et al. Trophic mechanisms mediating functional recovery following intrastriatal implantation. In: Dunnett SB, Bjorklund A, eds. Functional Neural Transplantation. New York: Raven Press, 1994: 140.
83. Yurek DM, Lu W, Hipkens S, Wiegand SJ. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Exp Neurol 1996; 137: 105-118.
84. Mott JL, Eken S, Bowenkamp K, et al. Effects of glial cell line-derived neurotrophic factor on dopaminergic transplants to the 6-OHDA denervated striatum. Soc Neurosci Abst 1996; 22(2): 592.10.
85. Zastrow DJ, Zawada WM, Clarkson, et al. Preincubation with growth factors improves survival of early mesencephalic grafts in hemiparkinsonian rats. Soc Neurosci Abst 1996; 22(2): 592.17.
86. Sanford E, Hong M, Poirier R, Guido M, Mendez I. Effect of the neurotrophic factor GDNF on transplanted dopaminergic cells treated acutely at the time of transplantation and during hibernation. Soc Neurosci Abst 1996; 22(3): 767.12.
87. Nakao N, Frodl EM, Duan WM, Widner H, Brundin P. Lazoroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91: 12408-12414.
88. Othberg A, Keep M, Brundin P, Lindvall O. Tirilazad mesylate increases survival of embryonic dopaminergic neurons in vitro. Soc Neurosci Abst 1996; 22(2): 592.12.
89. Nikkhah G, Cunningham MG, Jodicke A, Knappe U, Bjorklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson's model. Brain Res 1994: 633; 133-143.
90. Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced an antibody against myelin-associated growth inhibitors. Nature 1990; 343: 269-272.
91. Schwab ME. Myelin-associated inhibitors of neurite growth and regeneration in the CNS. Trends Neurosci 1990; 13: 452-455.
92. Schwab ME, Kapfhammer JP, Bandtlow CE. Inhibitors of neurite growth. Ann Rev Neurosci 1993; 16: 565-595.
93. Alexander GE, Delong MR. Microstimulation of the primate neostriatum. II. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J Neurophysiol 1985; 53: 1417-1430.
94. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-880.
95. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
96. Mendez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci 1996; 16(22): 7216-7227.
97. Brundin P, Strecker RE, Widner H, et al. Human fetal dopaminergic neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988; 70: 192-208.
98. Widner H, Brundin P, Bjorklund A, et al. Survival and immunogenicity of dissociated allogenic fetal neural dopamine rich grafts when implanted in the brains of adult mice. Exp Brain Res 1989; 76: 187-197.
99. Grabowska A, Lampson LA. Expression of class I and II major histocompatibility (MHC) antigens in the developing CNS. J Neural Transpla Plast 1992; 3: 204-205.
100. Boyer KL, Ansani A, Chan WC, et al. Immunological response to injury and grafting in the central nervous system. J Neural Transpla Plast 1992; 3: 202-203.
101. Freund TF, Bolam JP, Bjorklund A, et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. J Neurosci 1985; 5: 603-616.
102. Clarke DJ, Brundin P, Strecker RE, et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 1988; 73: 115-126.
103. Mendez I, Elisevich K, Flumerfelt B. Dopaminergic innervation of substance P-containing striatal neurons by fetal nigral grafts: an ultrastructural double-labeling immunocytochemical study. J Comp Neurol 1991; 308: 66-78.
104. Doucet G, Murata Y, Brundin P, et al. Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol 1989; 106: 1-19.
105. Robertson HA. Synergistic interactions of D1-and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias. Can J Neurol Sci 1992; 19: 147-152.
106. Kondoh T, Lae WC. Glutamate uptake blockade induces striatal dopamine release in 6-Hydroxydopamine rats with intrastriatal grafts: evidence for host modulation of transplanted dopamine neurons. Exp Neurol 1994; 127: 191-198.
107. Bjorklund A, Stenevi U, Dunnett SB, Gage FH. Cross-species neural grafting in a rat model of Parkinson's disease. Nature 1982; 298:652-654.
108. Freeman TB, Brandeis L, Pearson J, Flamm ES. Cross species grafts of embryonic rabbit mesencephalic tissue survive and cause behavioural recovery in the presence of chronic immunosuppression. In: Azmitia EC, Bjorklund A, eds. Cell and Tissue Transplantation into the Adult Brain. Ann NY Acad Sci, 1987: 699-702.
109. Huffaker TK, Boss BD, Morgan NT, et al. Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Exp Brain Res 1989; 77: 329-336.
110. Stromberg I, Adams C, Bygdeman M, et al. Long-term effects of human to rat mesencephalic xenografts on rotational behaviour, striatal dopamine receptor binding and mRNA levels. Brain Res Bull 1995; 38: 221-233.
111. Anton R, Kordower JH, Maidment NT, et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp Neurol 1994; 127: 207-218.
112. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707-1710.
113. Tasker RR, Siqueira J, Hawrylyshyn P, et al. What happened to VIM thalmotomy for Parkinson's disease? Appl Neurophysiol 1983; 46: 68-83.
114. Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractable tremor in post-levodopa era of Parkinson's disease patients. J Neurosurg 1991; 75: 723-730.
115. Jankovic J, Candoso F, Grossman R, et al. Outcome after stereotactic thalamotomy for Parkinsonian, essential, and other types of tremor. Neurosurgery 1995; 37: 680-687.
116. Matsumoto K. Reappraisal of ventrolateral thalamotomy for Parkinson's disease. In: Tasker RR, ed. Neurosurgery: State of the Art Reviews. Vol 2(1) Stereotactic Surgery. Philadelphia: Hanley and Belfus, 1987: 209-234.
117. Kelly PJ, Gillingham FJ. The long term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease: a 10-year follow up study. J Neurosurg 1980; 53: 332-337.
118. Benabid AL, Pollak P, Seigneuret E, et al. Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochir 1993; 58: 39-44.
119. Delong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285.
120. Bergman H, Wichmann T, Delong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438.
121. Laitinen LV, Bergenheim T, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
122. Svennilson E, Torvik A, Lowe R, et al. Treatment of parkinsonism by Stereotactic thermolesions in the pallidal region: a clinical evaluation of 81 cases. Acta Psychiatr Neurol Scand 1960; 35: 358-377.
123. Ceballos-Baumann AO, Obeso JA, Vitek JL, et al. Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease. Lancet 1994; 344: 814-815.
124. Lozano AM, Lang AE, Galvez-Jimnez N, et al. Effect of Gpi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-1387.
125. Benabid AL. Deep brain stimulation in Parkinson's disease: present state and outlook. Mediview, 4th International Congress of Movement Disorders 1996: 2.